Bevacizumab Results Favorable But Not Definitive


Chicago - A phase II trial of a new recombinant agent in the fight against melanoma has accrued 28 patients so far, yielding interesting data but so far no conclusive results, according to an abstract presented at this year's annual meeting of the American Society of Clinical Oncology.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.